Consistent with these observations, down-regulation of FLT3 by disrupting HOXA9 binding at the h-FLT3 enhancer led to decreased growth of MLL-r leukemia cells in vitro and in vivo and decreased their sensitivity to the FLT3 inhibitor, Gilteritinib. The gene discussed is KMT2A; the disease is leukemia.